Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Orphan Drug

PUBLISHER: Grand View Research | PRODUCT CODE: 1701345

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1701345

Chemotherapy-induced Neutropenia Treatment Market Size, Share & Trends Analysis Report By Treatment (Growth Factors, Antibiotics), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 195 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Chemotherapy-induced Neutropenia Treatment Market Growth & Trends:

The global chemotherapy-induced neutropenia treatment market is anticipated to reach USD 1.51 billion by 2030 and is expected to decline at a CAGR of -0.48% from 2025 to 2030, according to a new report by Grand View Research, Inc. This decline can be attributed to multiple factors, including the growing adoption of targeted cancer therapies and immunotherapies, which reduce the incidence of chemotherapy-induced neutropenia (CIN) compared to traditional chemotherapy. As precision medicine advances, oncologists are increasingly shifting towards treatment modalities that minimize myelosuppressive effects, thereby reducing the demand for CIN treatments. However, the rise of home healthcare and self-administrable therapies also presents an opportunity for pharmaceutical companies to develop user-friendly formulations that improve patient convenience.

Chemotherapy-Induced Neutropenia (CIN), a severe side effect of cancer treatment, poses significant risks for patients undergoing chemotherapy. As the prevalence of cancer cases continues to rise, the demand for effective CIN treatments is driving substantial growth in the healthcare sector. Businesses are capitalizing on advancements in treatment modalities, novel drug developments, and improved patient care solutions to address this critical condition. The market is witnessing increased investments in growth factors, antibiotics, antifungal agents, and other supportive therapies, ensuring better management of CIN and reducing associated complications.

To combat CIN effectively, growth factors play a vital role in stimulating white blood cell production, reducing the risk of infections in affected patients. Granulocyte Colony-Stimulating Factors (G-CSFs) are the primary treatment option, enhancing neutrophil recovery and minimizing chemotherapy delays. Leading pharmaceutical companies such as Amgen Inc., Sandoz, Teva Pharmaceutical Industries Ltd., Coherus BioSciences, Viatris Inc., and Biocon Biologics Inc. are at the forefront of G-CSF development.

Filgrastim is a widely used recombinant G-CSF that accelerates neutrophil recovery. Pegfilgrastim, a longer-acting version of Filgrastim, reduces the frequency of administration, while Lipegfilgrastim offers sustained neutrophil stimulation. Eflapegrastim is a novel, long-acting G-CSF providing effective prophylaxis against CIN, and Efbemalenograstim alfa is a next-generation therapy under development for enhanced neutrophil support. Additionally, Granulocyte-Macrophage Colony-Stimulating Factors (GM-CSFs) are expanding the therapeutic potential in neutrophil recovery. Key market players, including Pfizer Inc., Spectrum Pharmaceuticals, Inc., Evive Biotech, and G1 Therapeutics, Inc., are actively investing in research and development to improve the efficacy of these treatments.

However, even with the use of growth factors, CIN patients remain highly susceptible to bacterial and fungal infections, making the use of prophylactic and therapeutic antibiotics crucial. Prophylactic antibiotics play a key role in preventing infections in high-risk patients, while therapeutic antibiotics are administered when infections develop. Similarly, antifungal agents help combat opportunistic infections, ensuring comprehensive patient care. These treatments collectively form a multi-layered defense system against the risks posed by CIN. Prophylactic antibiotics serve as a preventive measure to reduce infection rates in neutropenic patients, whereas therapeutic antibiotics help manage bacterial infections that arise due to the weakened immune system. Meanwhile, antifungal agents provide an added layer of protection against invasive fungal infections, which can be life-threatening for patients undergoing chemotherapy.

In addition to these conventional treatment options, emerging therapies such as granulocyte transfusions and immunomodulatory agents are gaining attention as potential solutions for severe cases of neutropenia. Ongoing research and innovation are expected to enhance the effectiveness and accessibility of these treatment options, further strengthening the market landscape. The CIN treatment market is divided into branded drugs and biosimilars. Branded drugs continue to dominate due to their established efficacy, but biosimilars are rapidly gaining traction due to their cost-effectiveness and increasing adoption. As regulatory approvals expand and healthcare accessibility improves, biosimilar options are becoming more widely available, allowing more patients to benefit from advanced therapies without the financial burden of high-priced branded drugs.

Along with the development of new drug options, treatment delivery methods are also evolving. Parenteral administration remains the gold standard for CIN management, with intravenous (IV) and subcutaneous (SC) routes being preferred for G-CSFs and antibiotics to ensure rapid and effective results. However, oral options for prophylactic antibiotics and immunomodulatory agents are gaining popularity, offering greater convenience for outpatient care. This shift in administration methods aligns with the broader healthcare trend of enhancing patient accessibility and reducing hospital dependency for chronic care management.

As the burden of cancer continues to grow worldwide, the CIN treatment market is poised for substantial expansion. The increasing adoption of biosimilars, continuous advancements in drug development, and ongoing research into innovative therapies are collectively shaping the future of CIN management. With enhanced awareness, improved treatment protocols, and growing investment in supportive care, the future of CIN treatment is set to witness significant progress. These developments not only ensure better patient outcomes but also contribute to the overall advancement of global healthcare solutions.

Chemotherapy-induced Neutropenia Treatment Market Report Highlights:

  • On the basis of treatment, the growth factors segment dominated the market in 2024. The segment's dominance is attributable to its proven efficacy, widespread adoption in cancer treatment protocols, and continuous advancements in biosimilars.
  • Biosimilars led the drug type segment in market in 2024, driven by increasing regulatory approvals, cost-effectiveness, and growing adoption by healthcare providers..
  • On the basis of the route of administration, the parenteral segment dominated the market in 2024. Injectable formulations, particularly intravenous and subcutaneous G-CSFs, remain the primary mode of administration due to the rapid onset of their action and higher bioavailability compared to oral alternatives.
  • On the basis of distribution channel, the hospital pharmacies segment held the largest market share in 2024, driven by the high volume of chemotherapy conducted in hospital settings. Hospital pharmacies are the primary source of CIN treatment drugs, ensuring immediate availability and administration of critical medications
  • North America led the CIN treatment market, attributed to factors such as a well-established healthcare infrastructure, high awareness of cancer, and the availability of advanced treatment options. The region's strong focus on research and innovation further supports market growth.
Show more
Product Code: GVR-4-68040-198-8

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. Drug
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Distribution Channel & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Chemotherapy-Induced Neutropenia (CIN) Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
      • 3.3.3.1. Phase 1
      • 3.3.3.2. Phase 2
      • 3.3.3.3. Phase 3
    • 3.3.4. Pricing Analysis

Chapter 4. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2030
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 4.4. Growth Factors
    • 4.4.1. Growth Factors Market, 2018 - 2030 (USD Million)
  • 4.5. Antibiotics
    • 4.5.1. Antibiotics Market, 2018 - 2030 (USD Million)
  • 4.6. Antifungal Agents
    • 4.6.1. Antifungal Agents Market, 2018 - 2030 (USD Million)
  • 4.7. Other Treatments
    • 4.7.1. Other Treatments Market, 2018 - 2030 (USD Million)

Chapter 5. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Drug Business Analysis

  • 5.1. Drug Market Share, 2024 & 2030
  • 5.2. Drug Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug, 2018 to 2030 (USD Million)
  • 5.4. Branded Drugs
    • 5.4.1. Branded Drugs Market, 2018 - 2030 (USD Million)
  • 5.5. Biosimilars
    • 5.5.1. Biosimilars Market, 2018 - 2030 (USD Million)

Chapter 6. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2024 & 2030
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 6.4. Parenteral
    • 6.4.1. Parenteral Market, 2018 - 2030 (USD Million)
  • 6.5. Oral
    • 6.5.1. Oral Market, 2018 - 2030 (USD Million)

Chapter 7. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2030
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Chemotherapy-Induced Neutropenia (CIN) Treatment Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. Uk Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. China Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Amgen Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Sandoz
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Teva Pharmaceutical Industries Ltd
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Coherus BioSciences Inc.
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Coherus BioSciences Inc.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Viatris Inc.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Biocon Biologics Inc.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Pfizer Inc.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Spectrum Pharmaceuticals, Inc.
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Evive Biotech
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
    • 9.5.11. G1 Therapeutics, Inc.
      • 9.5.11.1. Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Strategic Initiatives
Show more
Product Code: GVR-4-68040-198-8

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 5 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 6 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 7 Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 9 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 10 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 11 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 12 North America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 14 U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 15 U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 16 U.S. Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Canada Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 18 Canada Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 19 Canada Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 20 Canada Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 21 Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 22 Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 23 Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 24 Mexico Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 26 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 27 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 28 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 29 Europe Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 UK Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 31 UK Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 32 UK Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 33 UK Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 35 Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 36 Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 37 Germany Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 38 France Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 39 France Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 40 France Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 41 France Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 43 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 44 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 45 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 Italy Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 48 Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 49 Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 50 Spain Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 52 Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 53 Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 54 Norway Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 56 Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 57 Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 Denmark Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 60 Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 61 Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 62 Sweden Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 67 Asia Pacific Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 68 Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 69 Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 70 Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 71 Japan Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 72 China Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 73 China Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 74 China Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 75 China Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 India Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 77 India Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 78 India Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 79 India Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 80 Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 81 Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 82 Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 83 Australia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 84 South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 85 South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 86 South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 87 South Korea Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 88 Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 89 Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 90 Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 91 Thailand Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 93 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 94 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 95 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 96 Latin America Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 97 Brazil Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 98 Brazil Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 99 Brazil Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 100 Brazil Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 101 Argentina Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 102 Argentina Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 103 Argentina Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 104 Argentina Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 108 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 109 Middle East & Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 110 South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 111 South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 112 South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 113 South Africa Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 117 Saudi Arabia Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 118 UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 119 UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 120 UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 121 UAE Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 123 Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 124 Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 125 Kuwait Chemotherapy-Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Chemotherapy-induced neutropenia (CIN) treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Treatment and Drug snapshot
  • Fig. 11 Route of administration and distribution channel snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Parent market value, 2024 (USD billion)
  • Fig. 14 Market dynamics
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 PESTLE analysis
  • Fig. 17 Chemotherapy-induced neutropenia (CIN) treatment market: Treatment outlook and key takeaways
  • Fig. 18 Chemotherapy-induced neutropenia (CIN) treatment market: Treatment movement analysis
  • Fig. 19 Growth factors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Antibiotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Antifungal agents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Other treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Chemotherapy-induced neutropenia (CIN) treatment market: Drug outlook and key takeaways
  • Fig. 24 Chemotherapy-induced neutropenia (CIN) treatment market: Drug movement analysis
  • Fig. 25 Branded drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Biosimilar market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Chemotherapy-induced neutropenia (CIN) treatment market: Route of administration outlook and key takeaways
  • Fig. 28 Chemotherapy-induced neutropenia (CIN) treatment market: Route of administration movement analysis
  • Fig. 29 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Chemotherapy-induced neutropenia (CIN) treatment market: Distribution channel market outlook and key takeaways
  • Fig. 32 Chemotherapy-induced neutropenia (CIN) treatment market: Distribution channel market movement analysis
  • Fig. 33 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Chemotherapy-induced neutropenia (CIN) treatment market revenue, by region, 2024 & 2030 (USD Million)
  • Fig. 37 Regional marketplace: Key takeaways
  • Fig. 38 North America chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 U.S. chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Cancer incidence, 2022 - 2045
  • Fig. 42 U.S. healthcare system: money flow
  • Fig. 43 Key country dynamics
  • Fig. 44 Canada chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Cancer incidence, 2022 - 2045
  • Fig. 46 Key country dynamics
  • Fig. 47 Mexico chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Cancer incidence, 2022 - 2045
  • Fig. 49 Regulatory framework
  • Fig. 50 Europe chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 UK chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Cancer incidence, 2022 - 2045
  • Fig. 54 Key country dynamics
  • Fig. 55 Germany chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Cancer incidence, 2022 - 2045
  • Fig. 57 Exclusivity formula
  • Fig. 58 Germany insurance coverage
  • Fig. 59 Key country dynamics
  • Fig. 60 France chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Cancer incidence, 2022 - 2045
  • Fig. 62 Key country dynamics
  • Fig. 63 Italy chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Cancer incidence, 2022 - 2045
  • Fig. 65 Key country dynamics
  • Fig. 66 Spain chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Cancer incidence, 2022 - 2045
  • Fig. 68 Key country dynamics
  • Fig. 69 Denmark chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Cancer Incidence, 2022 - 2045
  • Fig. 71 Key country dynamics
  • Fig. 72 Sweden chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Cancer incidence 2022 - 2045
  • Fig. 74 Key country dynamics
  • Fig. 75 Norway chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Cancer incidence, 2022 - 2045
  • Fig. 77 Rest of Europe chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Asia Pacific chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Japan chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 Cancer incidence, 2022 - 2045
  • Fig. 82 Japan pharmaceutical registration
  • Fig. 83 Key country dynamics
  • Fig. 84 China chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 85 Cancer incidence, 2022 - 2045
  • Fig. 86 Regulatory details: China
  • Fig. 87 Key country dynamics
  • Fig. 88 India chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 89 Cancer incidence, 2018 - 2030
  • Fig. 90 Key country dynamics
  • Fig. 91 Australia chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 92 Cancer incidence, 2018 - 2030
  • Fig. 93 Key country dynamics
  • Fig. 94 Thailand chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 95 Cancer incidence, 2018 - 2030
  • Fig. 96 Key country dynamics
  • Fig. 97 South Korea chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 98 Cancer incidence, 2018 - 2030
  • Fig. 99 Rest of Asia Pacific chemotherapy-induced neutropenia (CIN) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 100 Latin America chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Key country dynamics
  • Fig. 102 Brazil chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Cancer incidence, 2018 - 2030
  • Fig. 104 Key country dynamics
  • Fig. 105 Argentina chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Cancer incidence, 2018 - 2030
  • Fig. 107 Rest of Latin America chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 MEA chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Key country dynamics
  • Fig. 110 South Africa chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 Cancer incidence, 2018 - 2030
  • Fig. 112 Key country dynamics
  • Fig. 113 Saudi Arabia chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 114 Cancer incidence, 2018 - 2030
  • Fig. 115 Key country dynamics
  • Fig. 116 UAE chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 117 Cancer incidence, 2018 - 2030
  • Fig. 118 Key country dynamics
  • Fig. 119 Kuwait chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 120 Cancer incidence, 2018 - 2030
  • Fig. 121 Rest of MEA chemotherapy-induced neutropenia (CIN) treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 122 Company/competition categorization
  • Fig. 123 Strategy mapping
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!